Guardant Health, Inc. $GH Position Increased by Quantinno Capital Management LP

Quantinno Capital Management LP increased its position in shares of Guardant Health, Inc. (NASDAQ:GH) by 218.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,831 shares of the company’s stock after acquiring an additional 11,540 shares during the period. Quantinno Capital Management LP’s holdings in Guardant Health were worth $1,555,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. V Square Quantitative Management LLC purchased a new stake in shares of Guardant Health during the 4th quarter worth about $27,000. Elyxium Wealth LLC acquired a new stake in shares of Guardant Health during the 4th quarter valued at about $35,000. Parallel Advisors LLC grew its stake in shares of Guardant Health by 164.7% in the 4th quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock valued at $36,000 after buying an additional 219 shares in the last quarter. Ascentis Independent Advisors bought a new stake in shares of Guardant Health in the 1st quarter valued at approximately $38,000. Finally, Hollencrest Capital Management acquired a new position in Guardant Health in the first quarter worth approximately $41,000. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Insider Activity

In other Guardant Health news, Director Ian T. Clark sold 14,180 shares of the company’s stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $158.92, for a total transaction of $2,253,485.60. Following the completion of the sale, the director directly owned 2,975 shares in the company, valued at $472,787. This represents a 82.66% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Helmy Eltoukhy sold 100,000 shares of Guardant Health stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $126.30, for a total value of $12,630,000.00. Following the completion of the transaction, the chief executive officer owned 2,012,919 shares in the company, valued at $254,231,669.70. The trade was a 4.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 738,050 shares of company stock worth $98,859,427. Insiders own 5.60% of the company’s stock.

Guardant Health Trading Up 0.0%

Shares of Guardant Health stock opened at $165.11 on Thursday. The firm has a fifty day simple moving average of $149.24 and a 200-day simple moving average of $116.27. The stock has a market capitalization of $22.16 billion, a price-to-earnings ratio of -47.31 and a beta of 1.60. Guardant Health, Inc. has a 1-year low of $53.40 and a 1-year high of $176.58.

Wall Street Analysts Forecast Growth

GH has been the subject of a number of analyst reports. Morgan Stanley lifted their target price on shares of Guardant Health from $175.00 to $185.00 and gave the company an “overweight” rating in a research note on Tuesday, August 4th. Evercore restated an “outperform” rating and set a $200.00 price target on shares of Guardant Health in a research note on Monday, July 6th. Sanford C. Bernstein raised their price target on shares of Guardant Health from $175.00 to $200.00 and gave the company an “outperform” rating in a report on Thursday, July 2nd. Piper Sandler lifted their price objective on shares of Guardant Health from $135.00 to $193.00 and gave the company an “overweight” rating in a research note on Tuesday, August 4th. Finally, Mizuho upped their price objective on shares of Guardant Health from $175.00 to $200.00 and gave the stock an “outperform” rating in a report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $183.78.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.